66.7 F
New York
Monday, October 2, 2023



Serpin Pharma Awarded Competitive NCI Grant for SP16

Related Articles

Younok Dumortier Shin Honored as a Woman of the Month for July 2023 by P.O.W.E.R. – Professional Organization of Women of Excellence Recognized

West Windsor, NJ, September 29, 2023 --(PR.com)-- Younok Dumortier Shin of West Windsor, New Jersey, has been honored as a Woman of the Month for...

Meals on Wheels South Florida Receives Grant from Meals on Wheels America to Address Social Isolation and Loneliness in South Florida

Plantation, FL, September 28, 2023 --(PR.com)-- Meals on Wheels South Florida has announced today that it has received a $10,000 grant from Meals on Wheels...
Manassas, VA, September 20, 2022 –(PR.com)– The National Cancer Institute awarded Serpin Pharma a $400,000 competitive R43 grant for the Pre-clinical validation of phase II peptide LRP-1 agonist to treat and prevent chemotherapy-induced peripheral neuropathy.

The Principal Investigators are Serpin Pharma’s CEO and Executive Chairperson, Dr. Cohava Gelber and collaborator, Dr. Wendy Campana, Professor of Anesthesiology and Program in Neuroscience at the University of California, San Diego.

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequently experienced adverse side effect of patients receiving cancer treatments. Peripheral Neuropathy is the result of damage to the peripheral nerves and is associated with tingling, numbness, weakness, and pain, typically occurring in the hands and feet. Because of the chronic pain and other symptoms associated with CIPN, effective doses of chemotherapeutic agents are…

Read more…

Popular Articles